Carisma Therapeutics, Inc. (NASDAQ:CARM) to Post FY2028 Earnings of ($1.93) Per Share, Capital One Financial Forecasts

Carisma Therapeutics, Inc. (NASDAQ:CARM - Free Report) - Stock analysts at Capital One Financial issued their FY2028 earnings per share estimates for shares of Carisma Therapeutics in a report issued on Tuesday, April 2nd. Capital One Financial analyst N. Quibria anticipates that the company will post earnings of ($1.93) per share for the year. The consensus estimate for Carisma Therapeutics' current full-year earnings is ($2.13) per share.

Separately, HC Wainwright lowered their price target on Carisma Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Carisma Therapeutics currently has an average rating of "Buy" and a consensus target price of $9.60.

Carisma Therapeutics Stock Performance

CARM traded down $0.04 during trading on Wednesday, hitting $1.97. 264,069 shares of the stock were exchanged, compared to its average volume of 152,729. The firm has a market capitalization of $79.50 million, a P/E ratio of -0.58 and a beta of 0.95. The stock has a fifty day moving average price of $2.33 and a two-hundred day moving average price of $2.79. The company has a quick ratio of 7.53, a current ratio of 7.53 and a debt-to-equity ratio of 0.01. Carisma Therapeutics has a 1-year low of $1.86 and a 1-year high of $9.77.

Institutional Investors Weigh In On Carisma Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. CIBC Asset Management Inc purchased a new stake in shares of Carisma Therapeutics during the first quarter worth about $46,000. Tower Research Capital LLC TRC grew its stake in Carisma Therapeutics by 534.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 10,982 shares of the company's stock worth $46,000 after acquiring an additional 9,252 shares during the period. Barclays PLC acquired a new position in Carisma Therapeutics in the 2nd quarter valued at $47,000. Deutsche Bank AG acquired a new stake in shares of Carisma Therapeutics during the third quarter worth $52,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Carisma Therapeutics in the third quarter valued at $58,000. 44.27% of the stock is currently owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.